WMUK is contributing evidence to the Scottish Medicines Consortium’s forthcoming appraisal of ibrutinib in combination with rituximab for the treatment of adult patients with WM in Scotland. The appraisal will consider whether this new treatment can be made available to WM patients and funded by NHS Scotland.
Currently, WM patients in Scotland don’t have access to ibrutinib as a single or combined treatment on the NHS.
The process starts in April 2020 and takes around three months.
If you are currently receiving treatment for WM in Scotland, please get in touch at firstname.lastname@example.org to tell us your experiences.